BT
BTG (Boston Sci)
London UKFounded 19911,000 employees
Private CapbiotechAcquiredOncology
Platform: Interventional
Market Cap
N/A
All Drugs
4
Clinical Trials
6
Failed / Terminated
0
FDA Approved
1
Drug Pipeline (4 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Taladerotide | BTG-2637 | Phase 1 | 2 | CD38 | ObesityCF | ||
| Mavusertib | BTG-3363 | Approved | 1 | Tau | Celiac | ||
| Tixatinib | BTG-2040 | Phase 2 | 1 | WEE1 | Parkinson's | ||
| Teratenlimab | BTG-8806 | Phase 2 | 2 | CDK4/6 | Urothelial Ca |
Financial Documents
This company has been acquired — see parent company for financial filings.
Catalyst Events (4)